65 reports of this reaction
1.4% of all MECLIZINE HCL reports
#19 most reported adverse reaction
PERIPHERAL SWELLING is the #19 most commonly reported adverse reaction for MECLIZINE HCL, manufactured by Rising Pharma Holdings, Inc.. There are 65 FDA adverse event reports linking MECLIZINE HCL to PERIPHERAL SWELLING. This represents approximately 1.4% of all 4,811 adverse event reports for this drug.
Patients taking MECLIZINE HCL who experience peripheral swelling should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PERIPHERAL SWELLING is a less commonly reported adverse event for MECLIZINE HCL, but still significant enough to appear in the safety profile.
In addition to peripheral swelling, the following adverse reactions have been reported for MECLIZINE HCL:
The following drugs have also been linked to peripheral swelling in FDA adverse event reports:
PERIPHERAL SWELLING has been reported as an adverse event in 65 FDA reports for MECLIZINE HCL. This does not prove causation, but indicates an association observed in post-market surveillance data.
PERIPHERAL SWELLING accounts for approximately 1.4% of all adverse event reports for MECLIZINE HCL, making it a notable side effect.
If you experience peripheral swelling while taking MECLIZINE HCL, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.